Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen, with a price target of $224.00. The company’s shares closed yesterday at $130.13. Do ...

Biogen (NasdaqGS:BIIB) Reports Q1 Revenue Growth Despite Decline in Net Income Biogen (NasdaqGS:BIIB) reported a mixed financial performance with Q1 2025 earnings illustrating a decline in net income ...

Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist downgraded the stock, citing concerns over the company's growth prospects and high-risk ...

In a report released yesterday, Geoff Meacham from Citi maintained a Hold rating on Biogen, with a price target of $125.00. The company’s shares closed yesterday at $122.68. Take advantage of TipRanks ...

Looking at the chart above, BIIB's low point in its 52 week range is $153.62 per share, with $268.295 as the 52 week high point — that compares with a last trade of $156.32.